04:47 PM EDT, 06/27/2024 (MT Newswires) -- Samuel Kintz, Director, President and CEO, on June 25, 2024, sold 12,000 shares in Enliven Therapeutics ( ELVN ) for $259,902. Following the Form 4 filing with the SEC, Kintz has control over a total of 1,252,587 shares of the company, with 1,252,587 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1672619/000141588924018336/xslF345X03/form4-06272024_080620.xml